Ultragenyx Provides Topline Results And DMC Review From First Cohort Of Phase 1/2 Clinical Study Of DTX301, Says 2 of 3 Patients Didn't Show A Clinically Meaningful Change In Rate Of Ureagenesis Over 12 And 20 Weeks Respectively